TY - JOUR
T1 - Patient-reported outcomes and quality of life measures in atopic dermatitis
AU - Vakharia, Paras P.
AU - Cella, David
AU - Silverberg, Jonathan I.
N1 - Funding Information:
This publication was made possible with the support from the Agency for Healthcare Research and Quality (AHRQ), Grant Number K12 HS023011, and the Dermatology Foundation.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Atopic dermatitis (AD) is a complex and heterogeneous disorder with a profound symptom burden and harmful impact on multiple domains of quality of life (QOL). Many different patient-reported outcome (PRO) measures exist to assess clinical manifestations and QOL impairment in AD, but none comprehensively assess all aspects of the disease. This review addresses the PRO and QOL measures currently used in AD and their properties, strengths, weaknesses, and feasibility for assessing AD in randomized controlled trials and clinical practice. Currently, the patient-oriented eczema measure (POEM) has emerged as a preferred PRO for AD clinical manifestations, though no single instrument has developed as a preferred QOL measure. Validated PRO and QOL measures should be incorporated in all clinical trials of AD and in clinical practice where feasible.
AB - Atopic dermatitis (AD) is a complex and heterogeneous disorder with a profound symptom burden and harmful impact on multiple domains of quality of life (QOL). Many different patient-reported outcome (PRO) measures exist to assess clinical manifestations and QOL impairment in AD, but none comprehensively assess all aspects of the disease. This review addresses the PRO and QOL measures currently used in AD and their properties, strengths, weaknesses, and feasibility for assessing AD in randomized controlled trials and clinical practice. Currently, the patient-oriented eczema measure (POEM) has emerged as a preferred PRO for AD clinical manifestations, though no single instrument has developed as a preferred QOL measure. Validated PRO and QOL measures should be incorporated in all clinical trials of AD and in clinical practice where feasible.
UR - http://www.scopus.com/inward/record.url?scp=85053073205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053073205&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2018.05.011
DO - 10.1016/j.clindermatol.2018.05.011
M3 - Article
C2 - 30217274
AN - SCOPUS:85053073205
VL - 36
SP - 616
EP - 630
JO - Clinics in Dermatology
JF - Clinics in Dermatology
SN - 0738-081X
IS - 5
ER -